ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $161,222 | -36.7% | 30,362 | +13.7% | 0.00% | – |
| Q2 2023 | $254,518 | -36.2% | 26,707 | -26.4% | 0.00% | – |
| Q1 2023 | $399,223 | +7.2% | 36,293 | +44.2% | 0.00% | – |
| Q4 2022 | $372,546 | +7.1% | 25,172 | +38.3% | 0.00% | – |
| Q3 2022 | $348,000 | -7.4% | 18,204 | +3.1% | 0.00% | – |
| Q2 2022 | $376,000 | +28.3% | 17,649 | +16.2% | 0.00% | – |
| Q1 2022 | $293,000 | -16.8% | 15,191 | -10.5% | 0.00% | – |
| Q4 2021 | $352,000 | -8.3% | 16,969 | +5.5% | 0.00% | – |
| Q3 2021 | $384,000 | -22.0% | 16,087 | -10.8% | 0.00% | – |
| Q2 2021 | $492,000 | +2.5% | 18,033 | +8.6% | 0.00% | – |
| Q1 2021 | $480,000 | -85.3% | 16,605 | -85.7% | 0.00% | -100.0% |
| Q4 2020 | $3,261,000 | +1032.3% | 115,935 | +1081.2% | 0.00% | – |
| Q3 2020 | $288,000 | +101.4% | 9,815 | +107.7% | 0.00% | – |
| Q2 2020 | $143,000 | +31.2% | 4,725 | +29.2% | 0.00% | – |
| Q1 2020 | $109,000 | – | 3,658 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |